Clinical data | |
---|---|
Trade names | Inrebic |
Other names | Fedratinib hydrochloride, SAR302503; TG101348 |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | By mouth |
Drug class | Antineoplastic agent (inhibitor of Janus kinase 2 (JAK-2) and FLT-3)[1] |
Legal status | |
Legal status | |
Identifiers | |
| |
Chemical and physical data | |
Formula | C27H36N6O3S |
Molar mass | 524.68 g·mol−1 |
3D model (JSmol) | |
Density | 1.247 ± 0.06 g/cm3 |
| |
| |
(what is this?) |
Fedratinib, sold under the brand name Inrebic, is a medication used to treat myelofibrosis.[1] This includes primary myelofibrosis, post-polycythaemia vera myelofibrosis, and post-essential thrombocythaemia myelofibrosis.[3] It is used when there is an enlarged spleen or other symptoms.[3] It is taken by mouth.[1]
Common side effects include diarrhea, nausea, low red blood cells, and low platelets.[3] Other side effects may include encephalopathy.[1] It is an inhibitor of Janus kinase 2 (JAK-2) and FLT-3.[1]
Fedratinib was approved for medical use in the United States in 2019 and Europe in 2021.[1][3] In the United Kingdom a month of medication costs the NHS about £6,100 as of 2021.[4] This amount in the United States costs about 21,300 USD.[5]
References
edit- ^ a b c d e f g h "Fedratinib Monograph for Professionals". Drugs.com. Retrieved 10 December 2021.
- ^ "Inrebic- fedratinib hydrochloride capsule". DailyMed. Archived from the original on 6 April 2021. Retrieved 3 March 2021.
- ^ a b c d e f "Inrebic EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 7 March 2021. Retrieved 3 March 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Fedratinib". SPS - Specialist Pharmacy Service. 19 March 2018. Archived from the original on 11 December 2021. Retrieved 10 December 2021.
- ^ "Fedratinib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 10 December 2021.